HPV vaccination programme extended early

More than 70 per cent of 12-13 year old girls have already had their first HPV (human papillomavirus) jab since the vaccination campaign started in September, Public Health Minister Dawn Primarolo announced today. This figure will rise as more results come in.

The success of the campaign has prompted the Department of Health to announce that the catch up campaign to vaccinate girls aged 13-17 years will be brought forward to next year.

Early figures out today show that:

* 148 of the 152 Trusts have already started vaccinating young girls;

* 24 Trusts have reported uptake of 90 percent or more; and

* 124 Trusts are already giving the second dose of HPV.

Health Minister Dawn Primarolo said:

“This vaccination programme is about saving lives. It’s great news that more than 70 per cent of 12-13 year old girls have already had their first vaccine doses. I want to thank the local health teams, schools, girls and parents for making this programme such a success.

“Next year we’ll be investing more money so that Trusts can bring forward their catch-up programmes to cover 13-17 year old girls. This means that girls can be offered protection against cervical cancer earlier.”

The Department of Health will bring forward up to £17 million for Trusts in 2009 to implement this accelerated programme and ensure the roll out is a success.

Melynn Fanning, officer manager for Pinehurst Nephrology Associates, recently stated, “I am really happy with the services and I wish I found SpectraMedi sooner.” The services to be provided by U.S. based SpectraMedi Medical Transcription Service include EMR, electronic signature, online editing and automated faxing. “These services are more efficient and easy to use,” Ms. Fanning added.

SpectraMedi is pleased to have acquired this respected account, and the U.S. based medical transcription service provider looks forward to building a strong relationship with its new client. “We are privileged to have been chosen to provide medical transcription service to Pinehurst. Our value added services like EasyMove, EasyEdit, e-signature and automated faxing will relieve the practice from unnecessary clerical work,” stated Laura Dreher, the Head of Operations for U.S. based SpectraMedi.

About SpectraMedi
SpectraMedi, founded in 1999, is the leading U.S. based medical transcription service, with its main office in Syracuse, New York. SpectraMedi’s medical transcription services are easy to use, efficient and cost-effective. In addition to superior medical transcription service, U.S. based SpectraMedi also provides technical services such as electronic signature, electronic medical records, electronic health records, automated faxing, automated emailing, medical record sharing, and more. SpectraMedi serves a roster of prestigious U.S. based hospitals, clinics, and group practices throughout the country. SpectraMedi is known and admired for its high-quality medical transcription services, quick turnaround time, and affordable prices. For more information about SpectraMedi’s U.S. based medical transcription service, please visit www.spectramedi.com.

Plans to enhance Pathology services
Transforming NHS pathology services will improve quality, safety and efficiency in diagnostic tests, according to a two-year review into NHS Pathology Services published today.

The Independent Review of NHS Pathology Services, which was undertaken by Lord Carter of Coles, looked at making services more responsive to patients’ needs and highlights the potential for substantial annual savings.

Pathology services are vital, and play a key role in around 70 per cent of decisions on diagnosis and treatment. This includes blood tests for diabetes, biopsies to diagnose cancer, and tests for infections, such as tuberculosis. The growing use of genetics for preventative medicine and more personalised care is likely to increase the need for pathology services.

The Independent Review concluded that there is a strong case for transforming pathology. Recommendations include:

* Developing pathology networks with a single integrated management structure;

* Improving test turnaround times;

* Rapid adoption of new technology and approaches to delivering; services;

* Enhancing IT connectivity; and

* Centralising non-urgent and specialist work in accredited core laboratories.

Responding to the Review’s findings, the Department of Health Pathology Clinical Lead Dr Ian Barnes said:

“I am very grateful to Lord Carter and his panel for this thorough and comprehensive report.

“The review has found much good work already underway. Pathology is a vital service for patients and plays a key role in around 70 per cent of decisions on diagnosis and treatment. There is room for improvement and the Review has highlighted key areas for us to take forward. We have examined the review’s recommendations in detail and now begun the process to determine how services can be enhanced.”

Lord Carter of Coles said:

“The recommendations in this report will improve quality and safety standards for the public. I am grateful to the many people – pathologists, managers and others – who guided us to our conclusions. I am pleased that the Department has accepted our recommendations and shall take a keen interest in the implementation process as it proceeds.”

Professor Peter Furness, President of the Royal College of Pathologists said: “The Royal College of Pathologists welcomes Lord Carter’s report. We particularly appreciate the recommendations in relation to quality, the development of consolidated networks, and the need for an accreditation process that covers the diagnostic process from the decision to test to the delivery and interpretation of the results. We agree with the need for modernisation and improved efficiency. We share Lord Carter’s concerns achieving this aims will not be easy, but we are committed to assist.”

An impact assessment on the review’s recommendations will report in summer 2009. This process will be informed by three Strategic Health Authorities (SHAs) who will look at the practical implications of the recommendations.

Simon Brown, the chair of the Feng Shui Society in the UK, has completed an extensive review into potential opportunities designed to enhance the look and feel of Congleton.

Cheshire entrepreneur Dawn Gibbins, a keen Feng Shui practitioner, commissioned the special survey of her home town on behalf of the Congleton Business Group.

Dawn recently launched the Barefoot Living brand following her sale of leading international flooring company, Flowcrete.

Part of the new brand includes Barefoot Feng Shui, which is being developed as a social enterprise to bring to life the positive effect the ancient art can have on people’s day to day lives.

Dawn said: “Our mission is to make Britain a happy, healthy and prosperous nation with Feng Shui – and there is no better place to start than my home town of Congleton.

“Leading Feng Shui practitioner Simon Brown has carried out the survey and I am confident that by making some of the changes he suggests we can contribute to the health, well being and wealth of Congleton.”

Please contact Karen@ NO SPAM barefoot.co.uk to receive a copy of the report.

The Feng Shui Society is a not for profit enterprise whose mission is to promote the highest standards of Feng Shui. http://www.fengshuisociety.org.uk

“Clinique has always been on the cutting-edge of breakthrough science and skin care technology,” said Lynne Greene, Global President, Clinique Laboratories. “We are proud that we can meet the modern and discerning consumer’s unprecedented needs in our innovative way. Our collaboration with Allergan puts CLINIQUE MEDICAL in an ideal position to provide best-in-class professional skin care to both physicians and consumers alike.”

“CLINIQUE MEDICAL represents the latest innovation in Allergan’s commitment as a leader in medical aesthetics to the Science of Rejuvenation(TM) — that is to providing medical specialists and consumers with aesthetic products backed by science that deliver on a specific need in the market,” said Robert Grant, Allergan’s Corporate Vice President and President, Allergan Medical. “Combining the strengths of both Allergan and Clinique, the products in the CLINIQUE MEDICAL line leverage innovative technologies formulated to specifically address the explicit needs of patients’ skin when undergoing some of the most popular in-office procedures so they can have an optimal experience prior to and post-treatment.”

Named one of Allure magazine’s 2008 “Beauty Breakthroughs,” the products in the CLINIQUE MEDICAL Optimizing Regimen kit work together to help improve the skin’s receptivity to the benefits of laser skin resurfacing such as Intense Pulsed Light (IPL) or fractionated laser treatments, chemical peels such as 30% Trichloroacetic Acid (TCA) peels, and microdermabrasion.(1) Products in the kit also aid in the post-procedure process by helping to manage post-procedure visible excess redness and irritation, encourage even skin tone and enhance skin’s resilience to the visible signs of aging.

The CLINIQUE MEDICAL skin care line combines carefully selected ingredients with patent-pending components such as Probiotic Technology to create beautiful formulas that help prepare, support and maintain the skin pre- and post-treatment. The CLINIQUE MEDICAL Optimizing Regimen kit includes a Probiotic Cleanser, Skin Conditioning Treatment, Recovery Week Complex, Optimizing Treatment Cream and Daily SPF 38. The products included in the kit are also available for individual purchase. In addition, the CLINIQUE MEDICAL line also includes the Dry Spot Balm, an ultra-hydrating lip and facial spot balm designed to alleviate severe dryness and the associated discomfort related to some prescription medications.

Backed By Science

Two separate double-blind controlled studies consisting of 12 weeks of product use in two treatment cycles demonstrate the effectiveness of CLINIQUE MEDICAL in optimizing the outcome of non-surgical cosmetic procedures. The first study examined the use of CLINIQUE MEDICAL in conjunction with an IPL treatment (n=29), and the second study with a 30% TCA chemical peel (n=28). All participants in the studies were female between the ages of 35-65 and had never undergone the procedures.

At 12 weeks post-treatment in both studies, CLINIQUE MEDICAL was shown to optimize the benefits of the procedures, significantly improving many of the hallmark signs of aging, including the appearance of lines and wrinkles, age spots, skin radiance, skin firmness and skin tone. CLINIQUE MEDICAL also significantly reduced visible excess redness and irritation commonly associated with IPL treatments and 30% TCA chemical peels.

“In-office skin resurfacing treatments achieve results in similar ways — layers of skin are removed, and through the healing process, new, healthier-looking skin emerges. During this time, skin has a unique set of needs,” said dermatologist Vic Narurkar, MD, FAAD, Associate Clinical Professor, University of California Davis Medical School, and lead investigator in a study evaluating CLINIQUE MEDICAL used in conjunction with IPL and fractionated laser treatments. “Until now, a comprehensive skin care regimen designed specifically to complement these types of procedures hasn’t existed. With the introduction of CLINIQUE MEDICAL, we can now offer our patients a full system that conditions the skin to support optimal treatment results and helps to ease their recovery process.”

All products in the CLINIQUE MEDICAL skin care line are Allergy Tested, 100% Fragrance Free and contain no preservatives. CLINIQUE MEDICAL is available exclusively in skin care physicians’ offices nationwide. To learn more about CLINIQUE MEDICAL, visit www.cliniquemedical.com.

About Allergan Medical

Allergan Medical, a division of Allergan, Inc., offers the most comprehensive, science-based, aesthetic product offerings under its TOTAL FACIAL REJUVENATION(TM) portfolio, including BOTOX(R) Cosmetic; hyaluronic acid and collagen-based dermal fillers; and physician-dispensed skin care products. Allergan Medical also offers the industry’s widest range of silicone gel-filled and saline-filled breast implant options for reconstructive and aesthetic breast surgery, and leading minimally invasive devices for obesity intervention treatment.

About Allergan, Inc.

Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully. The Company employs approximately 8,000 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.

About Clinique

Introduced in 1968, Clinique was the first ever dermatologist-created, prestige cosmetic brand. Clinique’s mission has always been to provide the highest quality and most effective line of products to enhance every skin type and tone. The brand’s customized approach and quality products — all meticulously tested and carefully formulated with the latest science – have made Clinique one of the leading skin care authorities in the world. All makeup and skin care products are Allergy Tested and 100% Fragrance Free. Clinique offers products for men and women of all ages and ethnicities. Clinique is sold in more than 135 countries and territories, 17,000 sales locations and on www.clinique.com.

About The Estee Lauder Companies Inc. (NYSE: EL)

Founded in 1946, The Estee Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in over 140 countries and territories under the following brand names: Estee Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, MaEURcAaEURcC, Bobbi Brown, Tommy Hilfiger, Kiton, La Mer, Donna Karan, Aveda, Jo Malone, Bumble and bumble, Darphin, Michael Kors, American Beauty, Flirt!, Good Skin(TM), Grassroots, Sean John, Missoni, Daisy Fuentes, Tom Ford, Mustang, Coach, Ojon and Eyes by Design.

Allergan, Inc. and The Estee Lauder Companies Inc. Forward-Looking Statements

This press release contains “forward-looking statements,” including the statements by Mr. Grant, Ms. Greene and Dr. Narurkar and other statements regarding the safety, effectiveness, and market potential associated with the CLINIQUE MEDICAL product line. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan’s or The Estee Lauder Companies Inc.’s expectations and projections. Risks and uncertainties include, among other things, general industry and professional skin care channel conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products; inconsistency of treatment results among patients; the potential for product failures; potential difficulties in manufacturing new products; governmental laws and regulations affecting domestic and foreign operations and the ongoing success of the collaboration. Allergan and The Estee Lauder Companies Inc. expressly disclaim any intent or obligation to update these forward-looking statements except as required to do so by law.

Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan’s public periodic filings with the Securities and Exchange Commission, including the discussion under the heading “Risk Factors” in Allergan’s 2007 Form 10-K and Allergan’s Form 10-Q for the quarter ended June 30, 2008. Copies of Allergan’s press releases and additional information about Allergan are available on the World Wide Web at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 714.246.4636.

Additional information concerning these and other risk factors can also be found in press releases issued by The Estee Lauder Companies Inc., as well as in its filings with the Securities and Exchange Commission, including the discussion under the heading “Risk Factors” in The Estee Lauder Companies Inc. Form 10-K for the fiscal year ended July 30, 2008. Copies of The Estee Lauder Companies Inc. press releases, filings as well as additional information about the company, are available at www.elcompanies.com or you can contact The Estee Lauder Companies Inc. Investor Relations Department by calling 212.572.4184.

Clinique is a registered trademark of Clinique Laboratories, LLC

(C) 2008 Allergan, Inc. Irvine, CA 92612.

(1) Clinique data on file

SOURCE: Allergan, Inc.

Allergan, Inc.
Heather Katt 714.246.6224
katt_heather@allergan.com (media)

Caroline Van Hove 714.246.5134
vanhove_caroline@allergan.com (media)

Jim Hindman 714.246.4636 (investors)
Joann Bradley 714.246.4766 (investors)
Emil Schultz 714.246.4474 (investors)
or
The Estee Lauder Companies Inc. Contact
Dennis D’Andrea 212.572.4384 (investors)
or
Clinique Laboratories Contact
Sheila Munguia 212.572.6810 smunguia@clinique.com (media)

Copyright Business Wire 2008

Healing Hopes – Types of holistic healing

Collaborative Planning enables the creation and real-time monitoring of financial plans and forecasts. This web-based system, which is tightly integrated into Bedford Hospital’s existing COA Solutions eFinancials and eProcurement financial management systems, makes it quick and easy to input and analyse financial information and produce reports, eliminating time-consuming manual processes and the consolidation of spreadsheets.

Richard Mellor, Financial Controller at Bedford Hospital NHS Trust, says, “Having enjoyed significant time and cost savings since implementing COA Solutions’ eFinancials and eProcurement systems, we were confident that Collaborative Planning would deliver us additional operational benefits.”

Mellor continues, “The production of our reports used to be very labour intensive and involved printing out reams of paper and distributing them via the internal post. Collaborative Planning has eliminated these time-consuming manual processes by making financial information available on authorised staff’s PCs as soon as the reports are released.”

The system is also enabling managers to drill down to code level and see the current period’s transaction detail as and when required, rather than having to request a report from management accountants. This is reducing time spent on menial administrative tasks.

Historically, Bedford NHS’s financial forecasting was done by management accountants with the aid of spreadsheets. These figures would take up to a day to consolidate and would then be analysed and approved by a senior management accountant. With Collaborative Planning, financial information is quickly extracted, consolidated and communicated to authorised users, considerably improving efficiency.

Mellor explains, “Time previously spent consolidating forecasts has been eliminated thanks to Collaborative Planning. This is saving each management accountant one day per month, delivering an immediate cost saving whilst freeing-up time which can be used for more value-adding activities.”

Collaborative Planning is providing the Trust’s senior managers with greater control and ownership so that they have a more accurate and real-time view of budgets and forecasted spend. The Trust is also looking to provide service-line reports to managers via Collaborative Planning. Service-line reports are currently produced within the finance system as part of the monthly reporting cycle. Using Collaborative Planning, managers will be able to see more detail than is available on the hospital’s existing reports.

Collaborative Planning is also being used for budget setting, with final authorised budgets being loaded directly into the eFinancials general ledger. Mellor says, “Budget holders and finance can see at any point in time the status of budgets and add comments or amend forecasts in real-time. Collaborative Planning stores this information, tracks the changes and feeds this back into our eFinancials system bringing greater transparency and knowledge to the budget setting process.”

-ENDS-

About COA Solutions Ltd www.coasolutions.com

COA Solutions (formerly CedarOpenAccounts) is the UK’s leading supplier of integrated business management and information systems to public, private and not-for-profit organisations in the service sector. COA Solutions prides itself on getting close to its customers by understanding their businesses and responding to their business needs.

COA Solutions’ award-winning Smart Business Suite combines core financial management, procurement, human resource and payroll systems, integrated with a range of collaborative, document management and business intelligence solutions. These solutions extend the value and effectiveness of the finance, HR and payroll departments across the organisation and enable managers in the business to monitor, analyse and continually improve corporate performance.

COA Solutions has more than 500 experienced and professional staff supporting and servicing over 4,000 clients across the UK service sector including Companies House, Newcastle City Council, WHSmith, Royal Bank of Scotland, Aer Lingus, National Express Group, DFS, RSPB and Great Ormond Street Hospital for Children NHS Trust.

About Bedford Hospital NHS Trust http://www.bedfordhospital.nhs.uk/

Bedford Hospital NHS Trust provides a wide range of acute hospital services to its local community. It is one of several Hospital Trusts under the auspices of the East of England Strategic Health Authority. With a budget of £120m per annum the hospital provides services on an outpatient, day or inpatient basis. A number of specialties are carried out in partnership with other hospitals and we also work closely with hospital tertiary centres.

Bedford Hospital NHS Trust has earned a reputation for the high quality of its clinical and non-clinical services and has been named as one of the ‘top 40’ hospitals for several successive years by an independent data analyst CHKS.

COA Solutions Contacts:

Liz Ebbrell, COA Solutions
Liz.ebbrell@coasolutions.com
+44 (0)1625 856505 or 07917 634 705
www.coasolutions.com

Ben Carey, COA Solutions
Ben.carey@coasolutions.com
+44 (0)1625 856505
www.coasolutions.com

The authors identified 66 children who were diagnosed with NAFLD and had
extensive follow up data available for review. After the initial diagnosis,
four children developed type 2 diabetes and four children had increased liver
fibrosis. During follow up two children developed end-stage liver disease and
required a liver transplantation. However NAFLD recurred in the transplanted
liver in the two cases, with one case progressing to cirrhosis and requiring
re-transplantation. The study demonstrated that NAFLD in children is
associated with a significantly shorter long-term survival as compared to the
expected survival of the general population. Children with NAFLD had an almost
14-fold higher risk of dying or requiring liver transplantation than the
general population of same age and sex.

“There is currently no medication proven to be effective for NAFLD,”
development of medications that could treat NAFLD and NASH is an area of
intense research,” said Dr. Feldstein, “and it remains unclear whether there
are any clinical or laboratory features that can be used to identify the
subgroup of children with NAFLD that will develop advanced liver disease later
in life.”

“The most important recommendations for children with fatty liver are to
lose weight if they are overweight or obese, increase their physical activity,
follow a balanced diet and avoid unnecessary medications,” concluded Dr.
Feldstein.

Abstract title:

The natural history of nonalcoholic fatty liver disease in children: A
follow-up study up to 20 years.

AASLD is the leading medical organization for advancing the science and
practice of hepatology. Founded by physicians in 1950, AASLD’s vision is to
prevent and cure liver diseases. This year’s Liver Meeting, held in San
Francisco, California, October 31 – November 4, will bring together more than
7,000 researchers from 55 countries.

A pressroom will be available from November 1 at the annual meeting. For
copies of abstracts and press releases, or to arrange for pre-conference
research interviews contact Gregory Bologna at 703-299-9766. To pre-register,
call Ann Tracy at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org .

This release was issued through The Xpress Press News Service, merging
e-mail and satellite distribution technologies to reach business analysts and
media outlets worldwide. For more information, visit

http://www.XpressPress.com

SOURCE American Association for the Study of Liver Diseases

Related Resources:

Nurses in Society: starting the debate

State of the art metrics for nursing: a rapid appraisal

http://www.kcl.ac.uk/schools/nursing/nnru/

- 18 Weeks commitment met five months early

- C. difficile infection rates fall

NHS staff (in England) are making excellent progress against two key priority areas – to reduce waiting times to 18 weeks and cut Clostridium difficile (C. difficile) infections – statistics released today show.

Department of Health statistics for August show that nationally the NHS has met its commitment to ensure that 90% of patients who require admission to hospital and 95% of patients not needing admission, start treatment within 18 weeks of referral from their GP. This means that the operational standard has been met five months ahead of the end of December 2008 deadline.

The median referral to treatment time waited by patients who were admitted for treatment has come down from 18.8 weeks in March 2007 to 8 weeks in August this year and the median referral to treatment time waited by non-admitted patients has fallen from 7.4 weeks in August last year to 4.3 weeks in August this year. The number of patients waiting longer than six weeks for a diagnostic test has decreased by 97% since April 2006.

In addition, the latest Health Protection Agency quarterly figures (from April to June 2008) on C. difficile infections published today show a big drop in the key over-65 age group in which cases have dropped by 18% on the previous quarter and 38% since the same quarter in 2007. Overall, figures show a 21% decrease on the 2007/08 average and mean that the NHS is well on its way to delivering its target.

Secretary of State for Health Alan Johnson said,

“Waiting times and infection rates are key priorities for the public and that’s why the NHS is focusing its efforts in these areas. The figures published today are the result of the hard work and dedication of NHS staff and the right investment in resources.

“Twelve years ago it was common for patients to have to wait two years for an operation and in recent years, C. difficile infections were a significant challenge.

“Achieving our 18 Week commitment nationally five months early is great news for patients in England who can now expect much faster access to NHS care and it is immensely rewarding to see such a significant reduction in C. difficile following our investment in a comprehensive package of measures to drive down infections.”

18 Weeks Patient Champion Neil Betteridge said:

“When the Department of Health first announced the programme with its ambitious objectives, organisations like Arthritis Care naturally wondered whether the welcome attempt to reduce waiting times might inadvertently jeopardise other aspects of care. However, both the statistical and anecdotal evidence shows that patients are not only pleased to be waiting less time, but are telling us their overall quality of care has in their view improved. It really is ‘win-win’ and shows that putting the user experience at the heart of service delivery delivers practical benefits.”

There remain certain areas of the country and medical specialisms that have yet to achieve the 18 weeks commitment and the Department of Health will continue to work with the NHS to help all hospitals and Primary Care Trusts to achieve the target by the end of the year.

Reductions in C. difficile infections have been achieved by implementation of a package of measures including best practice clinical guidance and targeted support for those trusts who are most challenged. This is backed by substantial investment (£270 million a year by 2010/11) and the legal requirement for trusts to comply with the Hygiene Code. From April 2009 frontline staff, including the 5000 matrons we have now – more than double the number of last year – will also be able to report any concerns they have to the new regulator, the Care Quality Commission.

Care services minister shaping the future of care and support in London

People in London will today have the opportunity to shape Government policy and tell the Care Services Minister Phil Hope what they think about the future of the care and support system in England.

In 20 years time the number of people living in Greater London over the age of 65 will have risen to over 1 million, and the number of people over 85 will have risen to over 140,000.

As a result, the care system must change to meet the changing needs of society.

The engagement on the future of care and support involves members of the public, people who use services and their families joining the Care Service Minister Phil Hope to discuss their views on what kind of system they want to see in the future, as well as how it should be funded.

Phil Hope said:

“At the turn of the century there were 19 people working for every one retired. That number has now decreased to four working for every one retired. It’s vital I discuss, with the people of London, how we can create a high quality, affordable care and support system for a rapidly ageing population.

“The care and support system for the future should promote independence, choice and control for everyone. We are committed to creating a system in the future that meets the individual needs of our ageing population and their families. I urge people to get involved – the reform affects us all.”

In 20 years time a quarter of the entire adult population in England will be over 65 and the number of people over 85 will have doubled. We expect over 1.7 million more people to have care and support needs in 20 years time.

Millions of people across the country are involved with providing and using care and support. This reform is about finding a new way to help people stay active, care for family members, retain maximum dignity and respect and have the best possible quality of life.

Members of the public can contribute their views through a website http://www.careandsupport.direct.gov.uk